QuartzBio Team, Author at QuartzBio

About QuartzBio Team

This author has not written his bio yet.
But we are proud to say that QuartzBio Team contributed 92 entries already.

Entries by QuartzBio Team

Join QuartzBio at the SCOPE 2021 Virtual Conference for Clinical Operations Executives

Join QuartzBio at the SCOPE 2021 virtual conference for the “Clinical Biomarkers Operations and Innovation” track on March 2. PRESENTATION: “Centralizing PK, Clinical, and Exploratory Biospecimen Data to Streamline Trial Operations & Intelligence” Clinical samples are frequently a logistical headache – managed too often in Excel files that are time-consuming to update, and quickly fall […]

Translational Intelligence: On-Study Applications of Machine Learning to Integrated Biomarker and Clinical Data

February 12, 2021 — Integrating clinical and biomarker data enables both operational insights as well as scientific insights that can help teams make clinical trial decisions on-study. Our last article defined the synthesis of these insights as translational intelligence, with the potential to illuminate key insights in drug development just as business intelligence is used […]

Translational Intelligence: Unlocking Insights from Expansive Biomarker Data

February 3, 2021 — In this brief, we explore Translational Intelligence – that is, navigating the vast biomarker data ecosystem to quickly uncover insights that would be missed by visual inspection alone, and which enable translational teams to focus on the right pathways, biological mechanisms, and / or patient populations.

Generating Value from Public, Large Scale Biomedical Datasets — Video

February 1, 2021 — Translational and clinical researchers everywhere are harnessing public multiomics data sets to accelerate R&D. Renée Deehan, Ph.D., VP of Computational Biology at QuartzBio, described the enormous potential of public, real-world data at a panel discussion hosted by OBN.

Integrating Data and Knowledge from The Cancer Genome Atlas to Accelerate R&D

January 27, 2021 — Non-profit and governmental organizations have invested immense financial and labor resources, with generous contributions from participants, to create large-scale data sets. The Cancer Genome Atlas (TCGA) is one such publicly accessible resource, and represents a uniquely comprehensive collection of multiomic and clinical data, from which drug development researchers can derive knowledge […]

Centralizing PK, Clinical, and Exploratory Data to Streamline Biomarker-Centric Trial Operations

December 10, 2020 — Biomarker-guided trials frequently have an international footprint of sites to reach targeted patient populations and involve a complex network of specialty labs. Join us for our upcoming webinar, where QuartzBio’s Tobi Guennel will discuss how his team is breaking down data siloes to create actionable insights into availability and quality of […]

Precision Medicine Group Secures Major Investment from Blackstone

New York, NY & Bethesda, MD — November 20, 2020 — Precision Medicine Group (PMG) and Blackstone (NYSE: BX) today announced that PMG, a leading next-generation provider of drug development and commercialization services, has completed a major investment and recapitalization led by funds managed by Blackstone (“Blackstone”). The investment includes significant participation from Precision’s co-founders, […]

Enabling Translational Intelligence to Rapidly Surface On-study Operational and Scientific Insights

November 12, 2020 — In this article, QuartzBio Managing Director Scott Marshall discusses critical steps to integrating clinical, PK, and exploratory data on-study to advance operational and translational insights (without all the manual effort that has become all too common). With our experience working across dozens of clients and hundreds of studies, we’ve identified four […]

Reverse causal inferencing on molecular data from lung adenocarcinoma patients reveals a stem cell–like molecular subtype associated with pack-year history

November 9, 2020 — Advances in high throughput measurement technologies (omics data) have made it possible, and increasingly affordable, to generate high complexity, high volume data for oncology research. QuartzBio’s Renee Deehan poster, “Reverse Causal Inferencing on Lung Adenocarcinoma Patients Reveals a Stem Cell–Like Molecular Subtype Associated with Pack-Year History,” is an insightful look into […]

A Computational Approach to Modeling COVID-19

October 1, 2020 — In the months since March 2020, the biotech community has rallied to identify how our unique perspectives and skills can help with the COVID-19 pandemic. The computational biologists at QuartzBio are no different. QuartzBio’s Renee Deehan discusses how using existing published data to build a disease model can answer questions and […]